CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ACE inhibitor, angiotensin receptor blockerWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.24

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.24

There is one clinical trial.

Clinical Trials


1 Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial

ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients

NCT04353596 SARS-CoV-2 COVID-19 Drug: ACE inhibitor, angiotensin receptor blocker

Primary Outcomes

Description: The minimal value of the SOFA Score will be 0 and the maximal value 24 points. All-cause death is classified as the maximum score (24 points). In case of a subclinical disease progress without need for hospitalization, the SOFA score will be 0.

Measure: Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death

Time: 30 days

Measure: Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death

Time: 30 days

Secondary Outcomes

Description: minimum score is 0, maximum score is 24; higher score indicates poor outcome

Measure: Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score

Time: 30 days

Description: high-flow, continuous positive airway pressure therapy

Measure: Rates of non-invasive ventilation

Time: 30 days

Measure: Rates of renal replacement therapies

Time: 30 days

Measure: Change of viral burden

Time: 30 days

Measure: Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)

Time: 30 days

Measure: Number of patients with systolic/diastolic blood pressure > 180/120 mmHg

Time: 30 days

Description: with causal relationship to stopping of ACEI/ARB therapy

Measure: Hospitalisation due to cardiac decompensation

Time: 30 days

Measure: Rates of mechanical ventilation

Time: 30 days

Measure: Rates of clonal hematopoiesis of indeterminate potential (CHIP)

Time: 30 days


No related HPO nodes (Using clinical trials)